Avestar Capital’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.68M Sell
19,227
-2,566
-12% -$359K 0.17% 100
2025
Q4
$2.67M Buy
21,793
+2,639
+14% +$321K 0.17% 95
2025
Q3
$2.13M Buy
19,154
+1,040
+6% +$118K 0.14% 121
2025
Q2
$2.01M Buy
18,114
+4,296
+31% +$457K 0.14% 117
2025
Q1
$1.55M Buy
13,818
+5,521
+67% +$570K 0.13% 131
2024
Q4
$766K Buy
8,297
+1,362
+20% +$123K 0.07% 217
2024
Q3
$581K Buy
6,935
+1,534
+28% +$117K 0.06% 239
2024
Q2
$371K Buy
5,401
+568
+12% +$37.9K 0.04% 298
2024
Q1
$354K Sell
4,833
-235
-5% -$18.1K 0.04% 303
2023
Q4
$411K Buy
5,068
+1,274
+34% +$99.1K 0.05% 228
2023
Q3
$284K Buy
3,794
+694
+22% +$53.4K 0.04% 265
2023
Q2
$239K Buy
3,100
+596
+24% +$47.5K 0.04% 279
2023
Q1
$208K Sell
2,504
-168
-6% -$13.9K 0.04% 287
2022
Q4
$229K Buy
+2,672
New +$212K 0.04% 255
2021
Q2
Sell
-3,472
Closed -$224K 455
2021
Q1
$224K Buy
+3,472
New +$224K 0.05% 296
2020
Q3
Sell
-4,677
Closed -$360K 235
2020
Q2
$360K Sell
4,677
-7,476
-62% -$573K 0.16% 125
2020
Q1
$909K Buy
12,153
+355
+3% +$24.5K 0.5% 49
2019
Q4
$766K Sell
11,798
-325
-3% -$21.2K 0.43% 59
2019
Q3
$768K Buy
12,123
+226
+2% +$14.8K 0.48% 47
2019
Q2
$798K Buy
11,897
+5
+0% +$329 0.51% 45
2019
Q1
$769K Buy
11,892
+26
+0.2% +$1.73K 0.51% 44
2018
Q4
$739K Sell
11,866
-2
-0% -$140 0.5% 41
2018
Q3
$913K Sell
11,868
-166
-1% -$12.5K 0.53% 34
2018
Q2
$849K Sell
12,034
-9
-0.1% -$636 0.54% 36
2018
Q1
$904K Buy
12,043
+51
+0.4% +$4.05K 0.59% 29
2017
Q4
$855K Buy
+11,992
New +$911K 0.64% 19

Other funds holding GILD

Avestar Capital's GILD Position: Q1 2026 in Review

Avestar Capital reduced its Gilead Sciences (GILD) stake by 12% in Q1 2026, selling an estimated $359K and leaving 19,227 shares worth $2.68M. The position accounts for 0.17% of the portfolio, ranked #100.

Avestar Capital first reported a position in GILD in Q4 2017 and has held it in 26 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Avestar Capital held 19,227 shares of Gilead Sciences worth $2.68M as of Q1 2026.
  • Avestar Capital sold 2,566 Gilead Sciences shares in Q1 2026, an estimated $359K.
  • Gilead Sciences made up 0.17% of Avestar Capital's portfolio in Q1 2026, its #100 holding.
  • Avestar Capital first reported a position in Gilead Sciences in Q4 2017 and has held it in 26 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Avestar Capital's 13F filing for Q1 2026, filed 13 May 2026.